Mohamed Ali Ahmed
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mohamed Ali Ahmed has a total of 7 co-authors. Here are the top co-authors by number of shared publications:
Ahmed Emadeldeen Ghoneim
Faculty of Medicine, Tanta University, Tanta, Egypt
1 shared publication- Ahmed Gamal Elkhouly
Cardiothoracic Surgery Department, Tanta University, Tanta, Egypt
1 shared publication Alaa Basiouni Mahmoud
Faculty of Medicine, Tanta University, Tanta, Egypt
1 shared publicationAmr Abdel Elmonem Abdel Wahab
Faculty of Medicine, Tanta University, Tanta, Egypt
1 shared publication- Ayman Fahad Yousef
Department of Thoracic Surgery, King Saud Medical City, Riyadh, Saudi Arabia
1 shared publication - Mohammed Ishaq
Department of Thoracic Surgery, King Saud Medical City, Riyadh, Saudi Arabia
1 shared publication
Latest Publications
- Open Access
- 12 August 2026
- Published by Korean Society for Thoracic and Cardiovascular Surgery in Journal of Chest Surgery
- Vol. 59 (5) , 221-230
Efficacy and Safety of Combined Autologous Blood Patch and Doxycycline Pleurodesis for the Management of Persistent Air Leaks in Secondary Spontaneous Pneumothorax: A Randomized Controlled Trial
Mohamed Ahmed, M.D., Ph.D.1,2, Mohammed Y. Alamassi, M.D.2, Ayman F. Yousef, M.D.2, Mohammed S. Ishaq, M.D.2, Ahmed Gamal Elkhouly, M.D., Ph.D.1,2. J Chest Surg -0001;0:. https://doi.org/10.5090/jcs.26.076
- 12 August 2026
- Published by Korean Society for Thoracic and Cardiovascular Surgery in Journal of Chest Surgery
- Vol. 59 (5) , 221-230
Open AccessEfficacy and Safety of Combined Autologous Blood Patch and Doxycycline Pleurodesis for the Management of Persistent Air Leaks in Secondary Spontaneous Pneumothorax: A Randomized Controlled Trial
Mohamed Ahmed, M.D., Ph.D.1,2, Mohammed Y. Alamassi, M.D.2, Ayman F. Yousef, M.D.2, Mohammed S. Ishaq, M.D.2, Ahmed Gamal Elkhouly, M.D., Ph.D.1,2. J Chest Surg -0001;0:. https://doi.org/10.5090/jcs.26.076
- Open Access
- 7 September 2022
- Published by Springer Nature in The Cardiothoracic Surgeon
- Vol. 30 (1) , 1-6
Does prophylactic low-dose amiodarone decrease the incidence of postoperative atrial fibrillation after coronary artery bypass graft surgery? A randomized controlled trial
Background: Postoperative atrial fibrillation (POAF) occurs within 1 to 5 days after coronary artery bypass grafting (CABG), with a peak occurrence on the second day. This research aimed to assess the role of dose-low amiodarone in the prevention of POAF after CABG. Methods: This randomized controlled blind-single study was carried out on 150 patients undergoing elective CABG with sinus rhythm. Cases were randomized into two equal groups. The placebo group received matching placebo tablets. The amiodarone group received a prophylactic oral amiodarone 5 mg/kg/day for 6 days before and 6 days after surgery. Results: The incidence of POAF was significantly lower in the amiodarone group compared to the placebo group (16% vs 33.3%, P = 0.013) with a relative risk of 0.48 times (95% confidence interval: 0.26–0.88). The onset of POAF, percent of patients responded to medication, and time elapsed to respond to medication were insignificantly different between both groups. The mean (± SD) of ICU stay was 2.51 ± 1.11 days in the amiodarone group versus 3.31 ± 1.83 days in the placebo group, and the mean (± SD) of hospital stay duration was 10 ± 1.99 days in the amiodarone group versus 12.72 ± 2.23 days in the placebo group. The length of ICU admission and hospital stay was significantly lower in the amiodarone group than in the placebo group (P = 0.002 and < 0.001, respectively). Conclusions: Low-dose oral amiodarone was effective in POAF prevention after CABG with a lower length of ICU admission and hospital stay. Trial registration: Pan African Clinical Trials Register PACTR202101651961317. Registered on 21 January 2021
- 7 September 2022
- Published by Springer Nature in The Cardiothoracic Surgeon
- Vol. 30 (1) , 1-6
Open AccessDoes prophylactic low-dose amiodarone decrease the incidence of postoperative atrial fibrillation after coronary artery bypass graft surgery? A randomized controlled trial
Background: Postoperative atrial fibrillation (POAF) occurs within 1 to 5 days after coronary artery bypass grafting (CABG), with a peak occurrence on the second day. This research aimed to assess the role of dose-low amiodarone in the prevention of POAF after CABG. Methods: This randomized controlled blind-single study was carried out on 150 patients undergoing elective CABG with sinus rhythm. Cases were randomized into two equal groups. The placebo group received matching placebo tablets. The amiodarone group received a prophylactic oral amiodarone 5 mg/kg/day for 6 days before and 6 days after surgery. Results: The incidence of POAF was significantly lower in the amiodarone group compared to the placebo group (16% vs 33.3%, P = 0.013) with a relative risk of 0.48 times (95% confidence interval: 0.26–0.88). The onset of POAF, percent of patients responded to medication, and time elapsed to respond to medication were insignificantly different between both groups. The mean (± SD) of ICU stay was 2.51 ± 1.11 days in the amiodarone group versus 3.31 ± 1.83 days in the placebo group, and the mean (± SD) of hospital stay duration was 10 ± 1.99 days in the amiodarone group versus 12.72 ± 2.23 days in the placebo group. The length of ICU admission and hospital stay was significantly lower in the amiodarone group than in the placebo group (P = 0.002 and < 0.001, respectively). Conclusions: Low-dose oral amiodarone was effective in POAF prevention after CABG with a lower length of ICU admission and hospital stay. Trial registration: Pan African Clinical Trials Register PACTR202101651961317. Registered on 21 January 2021